(SVRA) Savara - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8051111016

SVRA: Respiratory, Pulmonary, Proteinosis, Autoimmune, Inhaled, Treatment

Savara Inc. (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company specializing in the development of therapies for rare respiratory diseases. The companys lead product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) currently in Phase 3 clinical trials for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare and life-threatening lung disorder. Savara is headquartered in Langhorne, Pennsylvania, and focuses on addressing unmet medical needs in pulmonary diseases. Web URL: https://www.savarapharma.com.

Based on the provided data, here is a 3-month forecast for Savara Inc. (SVRA):

Average Volume 20d: 698,482 shares. Last Price: $2.46. SMA 20: $2.74, SMA 50: $2.90, SMA 200: $3.77. ATR: 0.15. Market Cap: $461.66M. P/E: 0.00, P/E Forward: 0.00. P/B: 2.31. RoE: -41.60%. The stock is currently trading below its SMA 20, SMA 50, and SMA 200, indicating bearish momentum. Resistance levels at $4.8, $4.2, $3.7, and $3.1 may act as barriers to upward movement. The ATR of 0.15 suggests moderate volatility. Fundamentally, the companys negative RoE (-41.60%) reflects ongoing losses, typical for a clinical-stage biotech firm. The P/B ratio of 2.31 indicates that the market values the companys assets higher than their book value, potentially reflecting optimism about its pipeline. Over the next 3 months, SVRA is likely to remain under pressure due to its current price trend and resistance levels. However, any positive developments in its Phase 3 trials for molgramostim could act as a catalyst for upside movement. The stock may consolidate near its current levels, with potential downside risks tied to broader market conditions and clinical trial outcomes.

Additional Sources for SVRA Stock

SVRA Stock Overview

Market Cap in USD 527m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2017-06-01

SVRA Stock Ratings

Growth Rating 14.4
Fundamental -
Dividend Rating 0.0
Rel. Strength -26.3
Analysts 4.38/5
Fair Price Momentum 2.87 USD
Fair Price DCF -

SVRA Dividends

No Dividends Paid

SVRA Growth Ratios

Growth Correlation 3m 51.2%
Growth Correlation 12m -87.4%
Growth Correlation 5y 69.5%
CAGR 5y 7.23%
CAGR/Max DD 5y 0.11
Sharpe Ratio 12m -1.30
Alpha -38.68
Beta 0.886
Volatility 55.32%
Current Volume 373.6k
Average Volume 20d 606.4k
What is the price of SVRA stocks?
As of April 30, 2025, the stock is trading at USD 3.26 with a total of 373,559 shares traded.
Over the past week, the price has changed by +1.24%, over one month by +17.69%, over three months by +22.10% and over the past year by -29.28%.
Is Savara a good stock to buy?
Neither. Based on ValueRay Analyses, Savara is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 14.41 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SVRA as of April 2025 is 2.87. This means that SVRA is currently overvalued and has a potential downside of -11.96%.
Is SVRA a buy, sell or hold?
Savara has received a consensus analysts rating of 4.38. Therefor, it is recommend to buy SVRA.
  • Strong Buy: 4
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecast for SVRA stock price target?
According to ValueRays Forecast Model, SVRA Savara will be worth about 3.2 in April 2026. The stock is currently trading at 3.26. This means that the stock has a potential downside of -1.23%.
Issuer Forecast Upside
Wallstreet Target Price 9.4 189.6%
Analysts Target Price 9.6 193.3%
ValueRay Target Price 3.2 -1.2%